Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

• Published in: Cancer research communications Vol. 2; no. 11; pp. 1504 - 1519
• Main Authors: Paillasse, Michael R, Esquerré, Michael, Bertrand, Florie A, Poussereau-Pomié, Céline, Pichery, Mélanie, Visentin, Virgile, Gueguen-Dorbes, Geneviève, Gaujarengues, Florence, Barron, Pauline, Badet, Gaelle, Briaux, Anne, Ancey, Pierre-Benoit, Sibrac, David, Erdociain, Eric, Özcelik, Dennis, Meneyrol, Jérôme, Martin, Valérie, Gomez-Brouchet, Anne, Selves, Janik, Rochaix, Philippe, Battistella, Maxime, Lebbé, Céleste, Delord, Jean-Pierre, Dol-Gleizes, Frédérique, Bono, Françoise, Blanc, Isabelle, Alam, Antoine, Hunneyball, Ian, Whittaker, Mark, Fons, Pierre
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.11.2022
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Humans; Immunology; Immunotherapy; Mice; Neoplasms - drug therapy; Neovascularization, Pathologic - drug therapy; Protein Kinase Inhibitors - therapeutic use; Small Molecule Agents; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-3 - therapeutic use
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-22-0151

The receptor tyrosine kinase VEGFR-3 plays a crucial role in cancer-induced angiogenesis and lymphangiogenesis, promoting tumor development and metastasis. Here, we report the novel VEGFR-3 inhibitor EVT801 that presents a more selective and less toxic profile than two major inhibitors of VEGFRs (i.e., sorafenib and pazopanib). As monotherapy, EVT801 showed a potent antitumor effect in VEGFR-3-positive tumors, and in tumors with VEGFR-3-positive microenvironments. EVT801 suppressed VEGF-C-induced human endothelial cell proliferation and tumor (lymph)angiogenesis in different tumor mouse models. In addition to reduced tumor growth, EVT801 decreased tumor hypoxia, favored sustained tumor blood vessel homogenization (i.e., leaving fewer and overall larger vessels), and reduced important immunosuppressive cytokines (CCL4, CCL5) and myeloid-derived suppressor cells (MDSC) in circulation. Furthermore, in carcinoma mouse models, the combination of EVT801 with immune checkpoint therapy (ICT) yielded superior outcomes to either single treatment. Moreover, tumor growth inhibition was inversely correlated with levels of CCL4, CCL5, and MDSCs after treatment with EVT801, either alone or combined with ICT. Taken together, EVT801 represents a promising anti(lymph)angiogenic drug for improving ICT response rates in patients with VEGFR-3 positive tumors. The VEGFR-3 inhibitor EVT801 demonstrates superior selectivity and toxicity profile than other VEGFR-3 tyrosine kinase inhibitors. EVT801 showed potent antitumor effects in VEGFR-3-positive tumors, and tumors with VEGFR-3-positive microenvironments through blood vessel homogenization, and reduction of tumor hypoxia and limited immunosuppression. EVT801 increases immune checkpoint inhibitors' antitumor effects.